Jared Whitlock
@Jared_Whitlock
Features editor @endpts. Reach out privately on Signal: jaredwhitlock.73
For 3.5 years, I followed teenager Connor Dalby and family while a custom treatment was developed for his seizures. The journey revealed a lot about personalized medicine's failures, and promise. endpts.com/a-teenager-fac…
Sarepta's crisis week: How questions over patient deaths put the biotech's future in jeopardy w/ @leilei_wuu, via @endpts endpoints.news/how-sareptas-c…
In order to turn personalized therapies for rare diseases (like baby KJ) into a new standard of care, Birmingham said FDA should establish a dedicated oversight group within FDA to review personalized therapeutics, set transparent safety and ethics standards & ensure rigorous…
Former Intellia Tx CEO now operating partner at @khoslaventures Ness Birmingham published an op-ed in @thehill calling for the FDA to have a dedicated framework that clarifies the rules, requirements & incentives including a new pathway for bespoke therapeutics & n-of-1 drugs
Trump's online loyalty enforcer Laura Loomer has decided to target FDA's Vinay Prasad (a sentence I never thought I would write), from MAHA chronicler @maxonwifi endpoints.news/trump-loyalty-…
EXCLUSIVE: Sarepta Therapeutics’ $SRPT Duchenne therapy faces ‘arduous’ path back to market, senior FDA official says statnews.com/2025/07/22/fda… via @Jasonmmast and me.
Sarepta halts US shipments of Duchenne therapy, bowing to FDA endpoints.news/sarepta-halts-…
A must-read on the growing split inside RFK's MAHA movement:
My latest feature, on the growing revolt within key parts of MAHA after three mRNA vaccine approvals under @SecKennedy and @DrMakaryFDA. endpoints.news/fdas-continued…
🤫And if you work at @Sarepta or at the FDA on this issue, you can reach them on Signal (the confidential messaging app). Make sure you're using a personal device. Here are their handles: 🕵️♂️Jared: jaredwhitlock.73 🕵️♀️Lei Lei: leileiwu.24
Missed our show? You can see our emergency Sarepta episode here, where @endpts reporters @leilei_wuu + @Jared_Whitlock talk about reporting on biotech's biggest story right now. youtube.com/live/ktsbEth4p…
(reposted w/ link) Returned from Japan at midnight ➡️@endpts Post-Hoc Live about @Sarepta at 1:30 pm ET today. Join me, @ArmstrongDrew and @Jared_Whitlock to catch up on all that's happened around Sarepta and its DMD gene therapy last week endpoints.news/endpoints-live…
I'm looking forward to the conversation, and please be in touch with any tips you might have. Signal: jaredwhitlock.73
🎙️ Today on Endpoints News Post-Hoc Live, we're talking about @Sarepta. I'll be joined at 1:30pm by @Jared_Whitlock and @leilei_wuu about the company's showdown with the FDA over its hashtag #duchenne gene therapy + what comes next endpoints.news/endpoints-live…
Sarepta says it won't pull Duchenne gene therapy, setting up showdown with FDA - endpoints.news/sarepta-says-i…
Sarepta says it won't pull Duchenne gene therapy, setting up showdown with FDA endpoints.news/sarepta-says-i…
We are closely reporting on @Sarepta and the FDA's request to stop selling its Duchenne treatment If you have any tips, please contact me on Signal at jaredwhitlock.73, including if you work at Sarepta or were recently let go in this week's layoffs.
🚨FDA is asking Sarepta to pull DMD drug Elevidys endpoints.news/fda-asks-sarep…
$SRPT More confirmation here from @Jared_Whitlock of what we heard. The patient death occurred one month ago. Let that sink in when you think back to yesterday.
Another Sarepta patient has died, the company confirmed, this time in a study of its limb girdle therapy, @Jared_Whitlock reports: endpoints.news/sarepta-patien…
Another Sarepta patient has died, the company confirmed, this time in a study of its limb girdle therapy, @Jared_Whitlock reports: endpoints.news/sarepta-patien…
Sarepta Therapeutics said that a patient died in a clinical trial testing one of its gene therapies for limb-girdle muscular dystrophy, the latest death for a company that’s already under heightened scrutiny for safety concerns. endpoints.news/sarepta-patien…
The Trump administration disbanded a newborn screening panel. Advocates now face a harder path. “It’s not acceptance. It’s next-level rage," one parent told me. endpoints.news/the-trump-admi…
Endpoints biotech correspondent @ky_lahucik is in Kigali, Rwanda, this week to cover #IAS2025, the main conference for HIV science. We'll be posting updates, stories and photos from him here:
Chinese drugmakers have come a long way from their copycat days to challenge Western dominance on innovation. Our latest story visualizes this stunning advance, with data from @NorstellaCo with @hongjinshan and @spepechen: bloomberg.com/news/features/…